Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from China’s National Medical Products Administration for the investigational new drug application of SKB575, also known as HBM7575, a long-acting bispecific antibody for atopic dermatitis co-developed with Harbour BioMed. The therapy is designed to block thymic stromal lymphopoietin and a second undisclosed target to enhance efficacy and overcome resistance seen with single-target antibodies, with its extended half-life potentially enabling dosing intervals longer than three months and strengthening Kelun-Biotech’s position in the competitive dermatology and biologics market, although the company cautions that successful development and commercialization are not guaranteed.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong that focuses on the research, development and commercialization of innovative biologic therapies. The company targets immune-related and other serious diseases through advanced antibody and bispecific antibody technologies, often via global co-development partnerships.
Average Trading Volume: 557,058
Technical Sentiment Signal: Hold
Current Market Cap: HK$90.06B
For an in-depth examination of 6990 stock, go to TipRanks’ Overview page.